Publishing in face of the COVID-19 pandemic
- PMID: 32674930
- PMCID: PMC7357502
- DOI: 10.1016/j.ijantimicag.2020.106081
Publishing in face of the COVID-19 pandemic
Comment on
- doi: 10.1016/j.ijantimicag.2020.106063
- doi: 10.1016/j.ijantimicag.2020.105949
- doi: 10.1016/j.ijantimicag.2020.106056
References
-
- Glasziou PP. A deluge of poor quality research is sabotaging an effective evidence based response. BMJ. 2020;369 m1847.
-
- Machiels JD, Bleeker-Rovers CP, Hein ter R, Rahamat-Langendoen J, Mast de Q, Oever ten J. Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks? Int J Antimicrob Agents. 2020 doi: 10.1016/j.ijantimicag.2020.106056. - DOI - PMC - PubMed
-
- Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M. Hydroxy-chloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Mar 20 doi: 10.1016/j.ijantimicag.2020.105949. Online ahead of print. - DOI - PMC - PubMed
-
- Statement of the International Society of Antimicrobial Chemotherapy (ISAC) posted on its website, on April 3rd, 2020, https://www.isac.world/news-and-publications/official-isac-statement
-
- Statement of the International Society of Antimicrobial Chemotherapy (ISAC) posted on its website, on April 11th, 2020, https://www.isac.world/news-and-publications/isac-elsevier-statement.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources